Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy

• Egile Nagusiak: Rajbharan Yadav (Egilea), Suzanne Schubbert (Egilea), Patrick G. Holder (Egilea), Eugene Y. Chiang (Egilea), Nargess Kiabi (Egilea), Liz Bogaert (Egilea), Irene Leung (Egilea), Rumana Rashid (Egilea), Kendra N. Avery (Egilea), Christine Bonzon (Egilea), John R. Desjarlais (Egilea), Shomyseh Sanjabi (Egilea), Amy Sharma (Egilea), Michelle Lepherd (Egilea), Amy Shelton (Egilea), Pam Chan (Egilea), Yanqiu Liu (Egilea), Louis Joslyn (Egilea), Iraj Hosseini (Egilea), Eric G. Stefanich (Egilea), Amrita V. Kamath (Egilea), Matthew J. Bernett (Egilea), Vittal Shivva (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

IntroductionInterleukin 15 (IL-15) is a potential anticancer agent and numerous engineered IL-15 agonists are currently under clinical investigation. Selective targeting of IL-15 to specific lymphocytes may enhance therapeutic effects while helping to minimize toxicities.MethodsWe designed and built...